{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T20:52:40Z","timestamp":1792356760534,"version":"4.4.0"},"reference-count":32,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":1211,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2012,7]]},"DOI":"10.1111\/j.1365-2133.2012.10894.x","type":"journal-article","created":{"date-parts":[[2012,2,20]],"date-time":"2012-02-20T19:34:34Z","timestamp":1329766474000},"page":"44-49","source":"Crossref","is-referenced-by-count":84,"title":["Association between HLA-B*58:01 allele and severe cutaneous adverse reactions with allopurinol in Han Chinese in Hong Kong"],"prefix":"10.1093","volume":"167","author":[{"given":"M.L.S.","family":"Chiu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.H.L.","family":"Ng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.K.","family":"Yeung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.C-Y.","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.M.","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.H.","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Tomlinson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2012,5,8]]},"reference":[{"key":"10.1111\/j.1365-2133.2012.10894.x-BIB1|cit1","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1097\/00002281-200205000-00015","article-title":"Gout and hyperuricemia","volume":"14","author":"Wortmann","year":"2002","journal-title":"Curr Opin Rheumatol"},{"key":"10.1111\/j.1365-2133.2012.10894.x-BIB2|cit2","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1056\/NEJM199411103311906","article-title":"Severe adverse cutaneous reactions to drugs","volume":"331","author":"Roujeau","year":"1994","journal-title":"N Engl J Med"},{"key":"10.1111\/j.1365-2133.2012.10894.x-BIB3|cit3","doi-asserted-by":"crossref","DOI":"10.1111\/j.1468-3083.2011.04313.x","article-title":"Cutaneous adverse drug reactions to allopurinol: 10\u2003year observational survey of the dermatology department - Cagliari University (Italy)","author":"Atzori","year":"2011","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1111\/j.1365-2133.2012.10894.x-BIB4|cit4","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.jaad.2007.08.036","article-title":"Allopurinol is the most common cause of Stevens-Johnson syndrome and toxic epidermal necrolysis in Europe and Israel","volume":"58","author":"Halevy","year":"2008","journal-title":"J Am Acad Dermatol"},{"key":"10.1111\/j.1365-2133.2012.10894.x-BIB5|cit5","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1111\/j.1445-5994.2005.00790.x","article-title":"Risk estimates for drugs suspected of being associated with Stevens-Johnson syndrome and toxic epidermal necrolysis: a case-control study","volume":"35","author":"Lin","year":"2005","journal-title":"Intern Med J"},{"key":"10.1111\/j.1365-2133.2012.10894.x-BIB6|cit6","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1016\/S0140-6736(02)07873-X","article-title":"Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir","volume":"359","author":"Mallal","year":"2002","journal-title":"Lancet"},{"key":"10.1111\/j.1365-2133.2012.10894.x-BIB7|cit7","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1097\/01.fpc.0000199500.46842.4a","article-title":"Genetic susceptibility to carbamazepine-induced cutaneous adverse drug reactions","volume":"16","author":"Hung","year":"2006","journal-title":"Pharmacogenet Genomics"},{"key":"10.1111\/j.1365-2133.2012.10894.x-BIB8|cit8","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1111\/j.1528-1167.2007.01022.x","article-title":"Association between HLA-B*1502 allele and antiepileptic drug-induced cutaneous reactions in Han Chinese","volume":"48","author":"Man","year":"2007","journal-title":"Epilepsia"},{"key":"10.1111\/j.1365-2133.2012.10894.x-BIB9|cit9","doi-asserted-by":"crossref","first-page":"4134","DOI":"10.1073\/pnas.0409500102","article-title":"HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol","volume":"102","author":"Hung","year":"2005","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1111\/j.1365-2133.2012.10894.x-BIB10|cit10","doi-asserted-by":"crossref","first-page":"3567","DOI":"10.1093\/ndt\/gfr060","article-title":"HLA-B58 can help the clinical decision on starting allopurinol in patients with chronic renal insufficiency","volume":"26","author":"Jung","year":"2011","journal-title":"Nephrol Dial Transplant"},{"key":"10.1111\/j.1365-2133.2012.10894.x-BIB11|cit11","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1097\/FPC.0b013e32834282b8","article-title":"Positive and negative associations of HLA class I alleles with allopurinol-induced SCARs in Koreans","volume":"21","author":"Kang","year":"2011","journal-title":"Pharmacogenet Genomics"},{"key":"10.1111\/j.1365-2133.2012.10894.x-BIB12|cit12","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.2217\/14622416.9.11.1617","article-title":"HLA-B locus in Japanese patients with anti-epileptics and allopurinol-related Stevens-Johnson syndrome and toxic epidermal necrolysis","volume":"9","author":"Kaniwa","year":"2008","journal-title":"Pharmacogenomics"},{"key":"10.1111\/j.1365-2133.2012.10894.x-BIB13|cit13","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1097\/FPC.0b013e328330a3b8","article-title":"Strong association between HLA-B*5801 and allopurinol-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in a Thai population","volume":"19","author":"Tassaneeyakul","year":"2009","journal-title":"Pharmacogenet Genomics"},{"key":"10.1111\/j.1365-2133.2012.10894.x-BIB14|cit14","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1097\/FPC.0b013e3282f3ef9c","article-title":"A European study of HLA-B in Stevens-Johnson syndrome and toxic epidermal necrolysis related to five high-risk drugs","volume":"18","author":"Lonjou","year":"2008","journal-title":"Pharmacogenet Genomics"},{"key":"10.1111\/j.1365-2133.2012.10894.x-BIB15|cit15","doi-asserted-by":"crossref","first-page":"973","DOI":"10.2217\/pgs.10.77","article-title":"Pharmacogenetics of drug hypersensitivity","volume":"11","author":"Phillips","year":"2010","journal-title":"Pharmacogenomics"},{"key":"10.1111\/j.1365-2133.2012.10894.x-BIB16|cit16","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1111\/j.0001-2815.2004.00234.x","article-title":"HLA class I allele distribution of a Hong Kong Chinese population based on high-resolution PCR-SSOP typing","volume":"63","author":"Middleton","year":"2004","journal-title":"Tissue Antigens"},{"key":"10.1111\/j.1365-2133.2012.10894.x-BIB17|cit17","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1056\/NEJM199512143332404","article-title":"Medication use and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis","volume":"333","author":"Roujeau","year":"1995","journal-title":"N Engl J Med"},{"key":"10.1111\/j.1365-2133.2012.10894.x-BIB18|cit18","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1177\/106002809302700317","article-title":"Allopurinol hypersensitivity syndrome: a review","volume":"27","author":"Arellano","year":"1993","journal-title":"Ann Pharmacother"},{"key":"10.1111\/j.1365-2133.2012.10894.x-BIB19|cit19","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1111\/j.1365-2133.2006.07284.x","article-title":"Variability in the clinical pattern of cutaneous side-effects of drugs with systemic symptoms: does a DRESS syndrome really exist?","volume":"155","author":"Peyriere","year":"2006","journal-title":"Br J Dermatol"},{"key":"10.1111\/j.1365-2133.2012.10894.x-BIB20|cit20","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1038\/clpt.2009.252","article-title":"ALDEN, an algorithm for assessment of drug causality in Stevens-Johnson syndrome and toxic epidermal necrolysis: comparison with case-control analysis","volume":"88","author":"Sassolas","year":"2010","journal-title":"Clin Pharmacol Ther"},{"key":"10.1111\/j.1365-2133.2012.10894.x-BIB21|cit21","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1111\/j.1469-1809.1955.tb01285.x","article-title":"The estimation and significance of the logarithm of a ratio of frequencies","volume":"20","author":"Haldane","year":"1956","journal-title":"Ann Hum Genet"},{"key":"10.1111\/j.1365-2133.2012.10894.x-BIB22|cit22","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1001\/archderm.1993.01680220104023","article-title":"Clinical classification of cases of toxic epidermal necrolysis, Stevens-Johnson syndrome, and erythema multiforme","volume":"129","author":"Bastuji-Garin","year":"1993","journal-title":"Arch Dermatol"},{"key":"10.1111\/j.1365-2133.2012.10894.x-BIB23|cit23","doi-asserted-by":"crossref","first-page":"561","DOI":"10.2165\/00128071-200304080-00006","article-title":"Differential diagnosis of severe cutaneous drug eruptions","volume":"4","author":"Bachot","year":"2003","journal-title":"Am J Clin Dermatol"},{"key":"10.1111\/j.1365-2133.2012.10894.x-BIB24|cit24","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1001\/archderm.138.8.1019","article-title":"Correlations between clinical patterns and causes of erythema multiforme majus, Stevens-Johnson syndrome, and toxic epidermal necrolysis: results of an international prospective study","volume":"138","author":"Auquier-Dunant","year":"2002","journal-title":"Arch Dermatol"},{"key":"10.1111\/j.1365-2133.2012.10894.x-BIB25|cit25","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/0002-9343(84)90743-5","article-title":"Severe allopurinol toxicity description and guidelines for prevention in patients with renal insufficiency","volume":"76","author":"Hande","year":"1984","journal-title":"Am J Med"},{"key":"10.1111\/j.1365-2133.2012.10894.x-BIB26|cit26","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1007\/s11926-009-0019-z","article-title":"A critical reappraisal of allopurinol dosing, safety, and efficacy for hyperuricemia in gout","volume":"11","author":"Chao","year":"2009","journal-title":"Curr Rheumatol Rep"},{"key":"10.1111\/j.1365-2133.2012.10894.x-BIB27|cit27","first-page":"1646","article-title":"Dose adjustment of allopurinol according to creatinine clearance does not provide adequate control of hyperuricemia in patients with gout","volume":"33","author":"Dalbeth","year":"2006","journal-title":"J Rheumatol"},{"key":"10.1111\/j.1365-2133.2012.10894.x-BIB28|cit28","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1056\/NEJM199602153340707","article-title":"The management of gout","volume":"334","author":"Emmerson","year":"1996","journal-title":"N Engl J Med"},{"key":"10.1111\/j.1365-2133.2012.10894.x-BIB29|cit29","doi-asserted-by":"crossref","first-page":"623","DOI":"10.2165\/00003088-200746080-00001","article-title":"Clinical pharmacokinetics and pharmacodynamics of allopurinol and oxypurinol","volume":"46","author":"Day","year":"2007","journal-title":"Clin Pharmacokinet"},{"key":"10.1111\/j.1365-2133.2012.10894.x-BIB30|cit30","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1046\/j.1365-2230.1998.00311.x","article-title":"Allopurinol hypersensitivity syndrome: hypersensitivity to oxypurinol but not allopurinol","volume":"23","author":"Hamanaka","year":"1998","journal-title":"Clin Exp Dermatol"},{"key":"10.1111\/j.1365-2133.2012.10894.x-BIB31|cit31","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1007\/BF00577759","article-title":"Interaction of allopurinol and hydrochlorothiazide during prolonged oral administration of both drugs in normal subjects II. Kinetics of allopurinol, oxipurinol, and hydrochlorothiazide","volume":"72","author":"de Vries","year":"1994","journal-title":"Clin Investig"},{"key":"10.1111\/j.1365-2133.2012.10894.x-BIB32|cit32","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1056\/NEJMoa0706135","article-title":"HLA-B*5701 screening for hypersensitivity to abacavir","volume":"358","author":"Mallal","year":"2008","journal-title":"N Engl J Med"}],"container-title":["British Journal of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2133.2012.10894.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1111\/j.1365-2133.2012.10894.x\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,14]],"date-time":"2023-02-14T13:55:10Z","timestamp":1676382910000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/bjd\/article\/167\/1\/44\/6613956"}},"subtitle":["HLA-B*58:01 allele and allopurinol-induced SCAR"],"short-title":[],"issued":{"date-parts":[[2012,5,8]]},"references-count":32,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2012,7]]}},"URL":"https:\/\/doi.org\/10.1111\/j.1365-2133.2012.10894.x","relation":{},"ISSN":["0007-0963"],"issn-type":[{"value":"0007-0963","type":"print"}],"subject":[],"published":{"date-parts":[[2012,5,8]]}}}